Key Highlights

  • Driving Trial Success: GlyphAllo at 375 mg did not impair next-morning driving performance versus placebo in a Phase 1 simulation trial, meeting the primary endpoint.
  • Phase 2a Initiated: The first patient was dosed in October in a GlyphAgo proof-of-pharmacology trial for generalized anxiety disorder with sleep disturbance.
  • BUOY-1 Enrollment on Track: The Phase 2b trial of GlyphAllo in major depressive disorder continues enrolling, with topline data expected in the first half of 2027.
  • Cash Runway: $403.8 million in cash and investments as of September 30, 2026, expected to fund operations into 2029 across three mid-to-late-stage data readouts.

Seaport Therapeutics, Inc.(NASDAQ:SPTX), a clinical-stage company developing neuropsychiatric medicines, released its third-quarter 2026 financial results on November 2, 2026, alongside updates on two active clinical programs. The company is advancing GlyphAllo in major depressive disorder and GlyphAgo in generalized anxiety disorder, with a funded runway that extends through three anticipated late-stage data readouts.

GlyphAllo: Driving Data Clears a Critical Safety Hurdle

One of the more consequential milestones reported for the quarter was the outcome of a Phase 1 driving simulation trial of GlyphAllo, Seaport's allopregnanolone-based drug candidate. Sleep-disrupting side effects, particularly residual sedation that affects next-day functioning, have been a limiting Factor for neuroactive steroid therapies in the past. The Phase 1 trial directly tested whether GlyphAllo caused meaningful next-morning impairment.

The results showed that evening dosing of GlyphAllo at 375 mg did not impair next-morning simulated driving performance compared to placebo on Day 5 after multiple-day dosing. A key secondary endpoint was also met: a single 250 mg dose on Day 2 did not impair driving performance the following morning. No serious adverse events were reported during the trial, and the company intends to submit the data to the FDA as part of the ongoing development program.

This outcome supports the continued enrollment of BUOY-1, the Phase 2b trial in major depressive disorder that is simultaneously investigating GlyphAllo's antidepressant efficacy. BUOY-1 is a randomized, double-blind, placebo-controlled, globally enrolled trial, and topline data are expected in the first half of 2027. That readout is expected to be a potentially registration-enabling dataset.

GlyphAgo Enters the Clinic With a GAD Focus

GlyphAgo, Seaport's agomelatine-based candidate, moved into active patient dosing in October 2026 with the first patient enrolled in a Phase 2a proof-of-pharmacology trial targeting generalized anxiety disorder with sleep disturbance. The trial is designed to evaluate two dose levels — 16 mg/day and 32 mg/day — with primary endpoints focused on sleep outcomes including the Insomnia Severity index and EEG-based measures of sleep architecture. Additional endpoints cover anxiety symptoms.

Looking further ahead, Seaport plans to initiate a Phase 2/3 trial of GlyphAgo in GAD in the first half of 2027. That study is described as potentially registration-enabling. Topline data from the Phase 2a trial are expected in early 2028, with data from the Phase 2/3 study expected by year-end 2028.

CEO Daphne Zohar noted that the company is also evaluating indication expansion opportunities for the GlyphAllo program, including in generalized anxiety disorder — which could eventually allow a single asset to address both depression and anxiety treatment needs.

Risks

Both GlyphAllo and GlyphAgo are in mid-stage clinical development, and outcomes at Phase 2 do not guarantee Phase 3 success or regulatory approval. The neuropsychiatry field has a historically high rate of late-stage clinical failures, reflecting the complexity of central nervous system Drug Development and the difficulty of demonstrating meaningful efficacy in heterogeneous patient populations.

The company has no approved products and no commercial revenues, making its operations entirely dependent on its existing cash reserves. While $403.8 million in cash and investments provides a meaningful cushion through 2029, any material setback in either program — particularly BUOY-1 — would require the company to reassess its Capital allocation and potentially return to the capital markets.

What to Watch Next

The BUOY-1 topline readout, expected in the first half of 2027, is the most closely watched near-term event. A positive result in a well-designed, potentially registration-enabling Phase 2b trial would represent a meaningful step toward an NDA filing for GlyphAllo in MDD. Negative or ambiguous results would create significant uncertainty about the program's future.

The Phase 2a GlyphAgo data, while further out (early 2028), will establish whether the agomelatine delivery mechanism shows the pharmacological signal needed to advance into a pivotal-sized study.

Sector Context

Neuropsychiatric diseases represent one of the largest areas of unmet medical need globally, with major depressive disorder and generalized anxiety disorder affecting hundreds of millions of people. Seaport's pipeline addresses both conditions through differentiated mechanisms — allopregnanolone's modulation of GABA-A receptors and agomelatine's melatonin and serotonin receptor activity — rather than the monoamine reuptake inhibition that underlies most approved antidepressants and anxiolytics. This mechanistic differentiation is a core element of the company's scientific thesis about why these candidates may succeed where many predecessors have not.